Future Oncology · 2021 · 17 citations · 23 references
MedicineImmunologyOncologyBreast OncologyImmunotherapyMolecular OncologyBreast Cancer OncologyBreast Cancer RecurrenceCancer ImmunotherapyImmuno-oncology BiomarkersImmunotherapy For Breast CancerMolecular Tumor ProfilingBreast Cancer GenomicsBreast Cancer Molecular SubtypesBreast Cancer PrognosisIndividualized Treatment RegimensPrecision Medicine BiomarkersPrecision Medicine EvaluationT-cell Receptor Repertoire DiversityTumor Immunogenomics
Heterogeneity in breast cancer leads to diverse morphological features and different clinical outcomes. There are inherent differences in breast cancer between the populations in Asia and in western countries. The use of immune-based treatment in breast cancer is currently in the developmental stage. The VGH-TAYLOR study is designed to understand the genetic profiling of different subtypes of breast cancer in Taiwan and define the molecular risk factors for breast cancer recurrence. The T-cell receptor repertoire and the potential effects of immunotherapy in breast cancer subjects is evaluated. The favorable biomarkers for early detection of tumor recurrence, diagnosis and prognosis may provide clues for the selection of individualized treatment regimens and improvement in breast cancer therapy.
23
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah‐Jane Dawson, Dana W.Y. Tsui, Muhammed Murtaza et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Sherene Loi, Stefan Michiels, Roberto Salgado et al. · Annals of Oncology · 2014 · 1.3K citations
Medicine, Immunology, Oncology +15
Breast cancer intrinsic subtype classification, clinical use and future trends.
Xiaofeng Dai, Ting Li, Zhonghu Bai et al. · PubMed · 2015 · 912 citations
Medicine, Cancer Biology, Oncology +17